examining satiety and weight control benefits with a ... · compared to other potatoes and can...

© Kemin Industries, Inc. and its group of companies 2017. All rights reserved. ® ™ Trademarks of Kemin Industries, Inc., U.S.A.

Examining satiety and weight control

benefits with a natural potato extract


Who are weight conscious consumers?

DIETERS MAINTAINERS

Individuals on a diet trying to lose weight. Individuals who actively monitor what they

eat to manage weight.

29% of global female consumers follow a

weight loss diet, compared to 17% of male

consumers.2

Younger consumers are more inclined to eat

what they want and diet to compensate later.2

54% exercise at least weekly.2

Most common in the US, UK, India and

Japan.2

48% of global female consumers and 40% of

global male consumers.2

Older consumers more likely to stick to a

weight maintenance routine.2

70% exercise weekly.2

Much more of a focus among French and

Chinese consumers.2

Four out of five consumers are trying to lose weight or maintain their current weight.1

1International Food Information Council (IFIC) Foundation. (2015). Food and Health Survey Full Report. US data. 2Holmes, L. (2015). Euromonitor New Year, New Diet: How to Connect with the Weight Conscious Consumer.


Convenience and overall wellness

drive weight management supplement trends

Both niche and major producers are shifting to

general wellness positioning over weight

loss messaging.2

Weight management supplements with all natural

or organic ingredients are on the rise.2

Inclusive positioning to target busy, on-the-go

consumers is expected to keep the category growing.1

1Technavio. (2016). Global Weight Loss Supplement Market 2016-2020. 2Schmidt, C. (2015). Euromonitor Weight Management Products Growing in Consumer Health.

Image: 318286301


Slendesta®

Purposefully developed to support in weight control

Bryant, 1976. J Biochem 15: 3418-24; Barett-Ng, et al. 2003. J. Biol. Chem. 278: 31391-400

Images: 220894066, WT-07-0007 PyMOL, KH-IMG-SLE-Watermark-04

Recognized weight management as a growing consumer health concern.

Identified PI2 as a plant-based molecule with satiety benefits.

Discovered russet potatoes have higher levels of naturally occurring PI2

compared to other potatoes and can serve as a “botanical factory” for PI2.

• Natural constituent of the human diet, survives the cooking process • Enhances Cholecystokinin (CCK ) release >> Satiation and Satiety


How does it work?

Proteinase Inhibitor II (PI2), the active protein molecule in Slendesta,

promotes and extends the body’s natural release of CCK.

When food is eaten,

the small intestine

releases the peptide

signaling molecule

CCK.

CCK travels to the

brain and stomach

signaling these

organs to induce

feelings of fullness.

1

2

Image: 171343088


Blundell 1991.Trends in Pharmacology Science. Vol12

Blundell 1999. Schweiz Med Wochenschr. 129: 182-8.

CCK= Satiation and Satiety

FOOD

Satiety Satiation

Early Late

Sensory

Cognitive Post-ingestive

Post-absorptive

The Satiety Cascade


We partner with

farmers in the

USA to grow and

harvest potatoes.

We are moving

toward 100%

vertical integration.

Kemin is dedicated to providing a safe, traceable and efficacious ingredient.

We use a patented

gentle water-

based process to

extract the PI2.

This process

preserve and

protects the

integrity of PI2.

We demonstrated

the safety and

efficacy of this

potato extract in

human clinical

trials.

We perform strict

quality testing to

meet ensure a

product with

guaranteed levels

of PI2.

U.S. Patents 6,414,124; 6,872,544.

Images: KH-IMG-SLE-001, IMG-KI-00415, 109984472, 100258688, 228803698


• Studies assessing Satiation, Satiety and CCK

• Studies assessing Post-prandial Blood Glucose

• Studies assessing Weight Loss

Slendesta Research Clinical Trials


• Randomized, double-blind, placebo controlled crossover design

• 82 subjects recruited (BMI 19.0-29.9)

• Placebo or 30 mg PI2 administered 1h before an ad-libitum lunch meal

− Vegetable lasagna

• Efficacy criteria: Food intake and satiety

Hu et al. 2011. Kemin White Paper

KHTL 017-093 KEMIN PROPRIETARY DATA

Slendesta Research Satiety (Food Intake)

DMU Study (Des Moines University)

Results:

13% reduction in food intake after PI2 intake compared to placebo (p=0.0561)

•Effect more prominent in male (p=0.036)

Some indications of effect on post-prandial desire-to-eat and prospective food

consumption


Vasselli 1999

• Randomized, double-blind, crossover design

• 24 subjects (BMI 25-39)

• 30 mg PI2 in 80 kcal drink (236ml) administered 15 min prior to 550 kcal fixed lunch

• Satiety assessments (VAS) every 15min for 3.5h after lunch

Abstracts presented at North American Association for the Study of Obesity (NAASO) Annual Meeting 1999

30% reduction in post-meal hunger ratings

37% increase in fullness (3h following food intake)

Results:

Slendesta Research Satiety


ISU Study (Iowa State University)

• Randomized, double-blind, cross-over design

• 45 healthy adult women

• Three clinic visits

• Placebo, 15 mg, 30 mg PI2

− 0, 300, or 600 mg Slendesta® Potato Extract 5% Powder

− 60 min before a fixed 390 Kcal breakfast

• Measurements

− Fullness, hunger, desire to eat

− Prospective food consumption

− Glucose

− CCK

− Adverse events


Visual Analog Scale (VAS)

Zhu Y., et al. Food Funct. 2017 May 24;8(5):1988-1993


Results

• Slendesta Promotes Satiety

− Increase in fullness

− Decrease in:

− Hunger,

− Desire to eat,

− Prospective food consumption

• Increase of CCK release






*p < 0.05 compared to the placebo at the same time point

from pairwise comparisons of least squares means.

*

*

0

5

10

15

20

25

30

35

40

45

50

0 30 60 90 120 150 180 210

Ch

an

ge o

f fu

lln

ess (

mm

)

Time (min)

*

*

-50

-45

-40

-35

-30

-25

-20

-15

-10

-5

0

0 30 60 90 120 150 180 210

Ch

an

ge

of

hu

ng

er

(mm

)

Time (min)

-50

-45

-40

-35

-30

-25

-20

-15

-10

-5

0

0 30 60 90 120 150 180 210

Ch

an

ge

of

de

sir

e t

o e

at

(mm

)

Time (min)

* *

* *

-50

-45

-40

-35

-30

-25

-20

-15

-10

-5

0

0 30 60 90 120 150 180 210

Ch

an

ge

of

Pro

sp

ec

tive

Fo

od

C

on

su

mp

tio

n (

mm

)

Time (min)

*

*

300 mg Slendesta (15 mg PI2)


Placebo

0 = large urge, -100 = no urge

0 = very strong, -100 = very weak

0 = as hungry as I have ever felt; -100 = not hungry at all

0 = not at all full, 100 = very full;


Spreadbury Study


• 39 healthy adult men and women

• Placebo and two different active doses (30 min before a fix meal):

₋ 7.5 mg PI2 - (150 mg Slendesta)

₋ 15 mg PI2 - (300 mg Slendesta)

₋ 30 mg PI2 - (600 mg Slendesta)

Slendesta Research Post-Prandial Blood Glucose

Spreadbury et al. 2003. JANA. 6(1): 29-38.

Results:

• Reduction of 30-minutes post-prandial blood

glucose AUC relative to placebo (p<0.05)

₋ 7.5 mg PI2: no significant effect

₋ 15 mg PI2: 29.8%

₋ 30 mg PI2: 24.5%


ISU Study


• 45 healthy adult women

• Placebo, and two doses of active supplement (60 min before a fix breakfast)

− 15 mg PI2 - (300 mg Slendesta)

− 30 mg PI2 - (600 mg Slendesta)

Slendesta Research Post-Prandial Blood Glucose


• Reduction in glucose levels at

90min with 15 mg PI2 compared to

placebo (p = 0.034)

Results

-10

-5

0

5

10

15

20

25

30

35

0 30 60 90 120 150 180 210

Ch

an

ge o

f g

luco

se (

mg

/dL

)

Time (min)

*

*p < 0.05 compared to the placebo at the same time point from

pairwise comparisons of least squares means.



Placebo


RTL Study (Research Testing Laboratories)

• Multicenter, randomized, double-blind, placebo-controlled, parallel design

• 12 weeks, 4 Visits (exclusively for measurements)

• 240 healthy adults (BMI 25-35 kg/m2)

• No prescribed caloric intake, exercise or counseling

• Placebo, 15 mg PI2, 30 mg PI2

− 0, 300, or 600 mg Slendesta® Potato Extract 5% Powder

− 60 min before 2 largest meals

• Measurements − Weight

− Waistline

− Hipline

− Adverse events

Slendesta Research Weigh Loss

KHTL-017-044 KEMIN PROPRIETARY DATA -


RTL Study

• Statistically significant weigh loss compared to

placebo (p<0.05)

• Statistically significant reduction in waist and hip line

compared to placebo (p=0.03)

• Increasingly more subjects lost weight with PI2 supplied by Slendesta (p=0.03)

• 33% placebo

• 48% 15 mg

• 55% 30 mg

KHTL-017-044 KEMIN PROPRIETARY DATA

Slendesta Research Weight Loss



Placebo


Heartland Study

Slendesta Research Weight Loss

• Observational Study

• 28 healthy adults, 20 weeks supplementation (12 weeks + 8 weeks)

₋ 300 to 600 mg Slendesta® Potato Extract 5% Powder

₋ 15 mg to 30 mg PI2 60 min. before the largest meals

• No prescribed caloric intake or exercise

KHTL-017-045

0 4 8 12 16 20

-6

-5

-4

-3

-2

-1

0

Time, weeks

**

******

******

Weig

ht

Lo

ss,

kg

** p<0.01, ***p<0.001

KEMIN PROPRIETARY DATA

Results (baseline comparison):

• Statistically significant weight loss

₋ 90% of participants lost weight

• Statistically significant reduction in waist and hip measurements

₋ ↓ waist:hip

• Subject reported that the product helped them to eat less, feel full sooner and for longer


Incorporate Slendesta into your Daily Routine

• 300 to 600 mg Slendesta before the two main meals of the day

• Slendesta is available is different formulation suitable for distinct applications:

Food supplements

hard and soft gelatine capsules, tablets,

soluble powders, sachet, sticks

Foods & Beverages

bars, candy chews, chewing gums,

gummies, chocolates, drinks, soups

fruit-based shots and juices,

fruit & yogurt combo


Thank You

Get more information on Slendesta at

www.kemin.com

examining satiety and weight control benefits with a ... · compared to other potatoes and can...

Documents